The Society for Immunotherapy of Cancer (SITC) is pleased to announce the publication of a review manuscript titled "Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee."
Understanding the mechanisms that drive PD-L(1) inhibitor resistance and the development of predictive biomarkers is key in advancing the field of immunotherapy. To address this significant hurdle in the field, SITC convened the Biomarkers Committee, as well as additional stakeholders and experts, with the goal of exploring the importance of biomarker discovery for the purpose of enhanced clinical recognition of potential response/resistance. The group – including representatives from academia and industry – provided expertise in the following areas: current knowledge concerning the biology of response/resistance to PD-(L)1 inhibitors, general considerations for correlated biomarker development for single-agent and combination PD-(L)1 therapies, application of next-generation biomarkers, and challenges and solutions to clinical actionability of PD-(L)1 resistance/response biomarkers.